FcRN receptor antagonists in the management of myasthenia gravis
Myasthenia gravis (MG) is an autoimmune disorder characterized by autoantibodies specifically directed against proteins located within the postsynaptic membrane of the neuromuscular junction. These pathogenic autoantibodies can be reduced by therapies such as plasma exchange, IVIG infusions and othe...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2023.1229112/full |
| _version_ | 1797754439897972736 |
|---|---|
| author | Vinaya Bhandari Vera Bril |
| author_facet | Vinaya Bhandari Vera Bril |
| author_sort | Vinaya Bhandari |
| collection | DOAJ |
| description | Myasthenia gravis (MG) is an autoimmune disorder characterized by autoantibodies specifically directed against proteins located within the postsynaptic membrane of the neuromuscular junction. These pathogenic autoantibodies can be reduced by therapies such as plasma exchange, IVIG infusions and other immunosuppressive agents. However, there are significant side effects associated with most of these therapies. Since there is a better understanding of the molecular structure and the biological properties of the neonatal Fc receptors (FcRn), it possesses an attractive profile in treating myasthenia gravis. FcRn receptors prevent the catabolism of IgG by impeding their lysosomal degradation and facilitating their extracellular release at physiological pH, consequently extending the IgG half-life. Thus, the catabolism of IgG can be enhanced by blocking the FcRn, leading to outcomes similar to those achieved through plasma exchange with no significant safety concerns. The available studies suggest that FcRn holds promise as a versatile therapeutic intervention, capable of delivering beneficial outcomes in patients with distinct characteristics and varying degrees of MG severity. Efgartigimod is already approved for the treatment of generalized MG, rozanolixizumab is under review by health authorities, and phase 3 trials of nipocalimab and batoclimab are underway. Here, we will review the available data on FcRn therapeutic agents in the management of MG. |
| first_indexed | 2024-03-12T17:33:27Z |
| format | Article |
| id | doaj.art-39d941d860e942a5aab48ba46f2534b4 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-03-12T17:33:27Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-39d941d860e942a5aab48ba46f2534b42023-08-04T15:40:45ZengFrontiers Media S.A.Frontiers in Neurology1664-22952023-08-011410.3389/fneur.2023.12291121229112FcRN receptor antagonists in the management of myasthenia gravisVinaya BhandariVera BrilMyasthenia gravis (MG) is an autoimmune disorder characterized by autoantibodies specifically directed against proteins located within the postsynaptic membrane of the neuromuscular junction. These pathogenic autoantibodies can be reduced by therapies such as plasma exchange, IVIG infusions and other immunosuppressive agents. However, there are significant side effects associated with most of these therapies. Since there is a better understanding of the molecular structure and the biological properties of the neonatal Fc receptors (FcRn), it possesses an attractive profile in treating myasthenia gravis. FcRn receptors prevent the catabolism of IgG by impeding their lysosomal degradation and facilitating their extracellular release at physiological pH, consequently extending the IgG half-life. Thus, the catabolism of IgG can be enhanced by blocking the FcRn, leading to outcomes similar to those achieved through plasma exchange with no significant safety concerns. The available studies suggest that FcRn holds promise as a versatile therapeutic intervention, capable of delivering beneficial outcomes in patients with distinct characteristics and varying degrees of MG severity. Efgartigimod is already approved for the treatment of generalized MG, rozanolixizumab is under review by health authorities, and phase 3 trials of nipocalimab and batoclimab are underway. Here, we will review the available data on FcRn therapeutic agents in the management of MG.https://www.frontiersin.org/articles/10.3389/fneur.2023.1229112/fullneonatal Fc receptor (FcRn)myasthenia gravis (MG)immunoglobulins (IgG)clinical trialsFc receptor inhibitors |
| spellingShingle | Vinaya Bhandari Vera Bril FcRN receptor antagonists in the management of myasthenia gravis Frontiers in Neurology neonatal Fc receptor (FcRn) myasthenia gravis (MG) immunoglobulins (IgG) clinical trials Fc receptor inhibitors |
| title | FcRN receptor antagonists in the management of myasthenia gravis |
| title_full | FcRN receptor antagonists in the management of myasthenia gravis |
| title_fullStr | FcRN receptor antagonists in the management of myasthenia gravis |
| title_full_unstemmed | FcRN receptor antagonists in the management of myasthenia gravis |
| title_short | FcRN receptor antagonists in the management of myasthenia gravis |
| title_sort | fcrn receptor antagonists in the management of myasthenia gravis |
| topic | neonatal Fc receptor (FcRn) myasthenia gravis (MG) immunoglobulins (IgG) clinical trials Fc receptor inhibitors |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2023.1229112/full |
| work_keys_str_mv | AT vinayabhandari fcrnreceptorantagonistsinthemanagementofmyastheniagravis AT verabril fcrnreceptorantagonistsinthemanagementofmyastheniagravis |